Challenges to the Application of Integrated, Personalized Care for Patients with COPD-A Vision for the Role of Clinical Information
- PMID: 32370150
- PMCID: PMC7290491
- DOI: 10.3390/jcm9051311
Challenges to the Application of Integrated, Personalized Care for Patients with COPD-A Vision for the Role of Clinical Information
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a complex disease defined by airflow limitation and characterized by a spectrum of treatable and untreatable pulmonary and extra-pulmonary disease characteristics. Nonpharmacological management related to physical activity, physical capacity, body composition, breathing and energy-saving techniques, coping strategies, and self-management is as important as its pharmacological management. Most patients with COPD carry other chronic diagnoses and this poses a key challenge, as it lowers the quality of life, increases mortality, and impacts healthcare consumption. A personalized, multi-, and interprofessional approach is key. Today, healthcare is poorly organized to meet this complexity with the isolation between care levels, logic silos of the different healthcare professions, and lack of continuity of care along the patient's journey with the healthcare system. In order to meet the criteria for integrated, personalized care for COPD, the structural capabilities of healthcare to support a comprehensive approach and continuity of care needs improvement. COPD is preeminently a disease that requires a transition from a reactive single-specialty approach to a proactive interprofessional approach. In this study, we discuss the issues that need to be addressed when moving from current health care practice to a person-centered model where the care processes and information are aligned to the individual personal needs of the patient.
Keywords: COPD; care plan; chronic disease; clinical health informatics; multimorbidity; person-centered care.
Conflict of interest statement
L.E.G.W.V. reports personal fees from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, Pulmonx, Menarini and GSK outside the submitted work. K.K.O. and A.J.v.t.H. declare no conflict of interest. A.A. reports personal fees from AstraZeneca and Novartis outside the submitted work. A.U. reports personal grants from AstraZeneca, GSK, Chiesi and he serves on the Board of Directors for Verona Pharma outside the submitted work. M.I. reports serving on the board (non-remunerated) of ICHOM.org, a not for profit entity devoted to the production of outcomes measurement sets for health care, outside the submitted work.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
